5414x Apr 2026

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights: : Introduced next-generation automated flow cell lines and

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards. Interim results for the 6 months ended 30 June 25 : 58

: £12.9 million (+27.4%), supported by synthetic biology.

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25 driven by AMR and EMEAI growth.

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :